Bafna Pharmaceuticals Ltd (BAFNAPH) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 852453, "name": "Bafna Pharma.", "stock_name": "Bafna Pharma.", "full_name": "Bafna Pharmaceuticals Ltd", "name_url": "stocks-analysis/bafna-pharma", "exchange": 1, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "131.10", "chg": -3.09, "chgp": "-2.3%", "dir": -1, "prev_price": "134.19", "mcapval": "317.00 Cr", "mcap": "Micro Cap", "scripcode": 532989, "symbol": "BAFNAPH", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "India SENSEX", "isin": "INE878I01022", "curr_date": "May 06", "curr_time": "", "bse_nse_vol": "1.08 k", "exc_status": "Active", "traded_date": "May 06, 2026", "traded_date_str": "2026 05 06", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bafna-pharma-852453-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Bafna Pharmaceuticals Ltd Valuation Shifts to Fair Amid Mixed Market Performance", "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-valuation-shifts-to-fair-amid-mixed-market-performance-3976717", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BafnaPharmaceut_valuationdot_3976717.png", "date": "2026-05-06 08:00:36", "description": "Bafna Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade as of late April 2026. Despite a recent day decline of 3.76%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more balanced price attractiveness compared to its historical and peer averages within the Pharmaceuticals & Biotechnology sector." }, { "title": "Bafna Pharmaceuticals Ltd Upgraded to Sell on Technical Improvements Despite Expensive Valuation", "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-ltd-upgraded-to-sell-on-technical-improvements-despite-expensive-valuation-3969600", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_mojoScore_3969600.png", "date": "2026-04-30 08:16:04", "description": "Bafna Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 Apr 2026, reflecting a nuanced shift in its technical outlook despite persistent valuation and fundamental challenges. The upgrade is primarily driven by improved technical indicators, while valuation metrics have become more expensive and financial trends remain flat, prompting a cautious stance for investors." }, { "title": "Bafna Pharmaceuticals Downgraded to Strong Sell Amid Valuation and Technical Concerns", "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-downgraded-to-strong-sell-amid-valuation-and-technical-concerns-3963779", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_mojoScore_3963779.png", "date": "2026-04-27 08:13:46", "description": "Bafna Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 24 April 2026, reflecting deteriorating technical indicators and an expensive valuation profile despite its strong long-term returns. The micro-cap pharmaceutical company faces challenges across quality, valuation, financial trends, and technical parameters, prompting a reassessment of its investment appeal." }, { "title": "Bafna Pharmaceuticals Gains 2.43%: 2 Key Factors Driving the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-gains-243-2-key-factors-driving-the-week-3962552", "imagepath": "", "date": "2026-04-25 15:01:02", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>Apr 20:</strong> Stock opens strong at Rs.142.10 (+4.72%)</p>\n <p><strong>Apr 21:</strong> Sharp correction to Rs.135.00 (-5.00%)</p>\n <p><strong>Apr 23:</strong> Surges to upper circuit at Rs.138.73 amid strong buying</p>\n <p><strong>Apr 24:</strong> Valuation shifts signal price attractiveness challenges</p>\n <p><strong>Apr 24:</strong> Week closes at Rs.139.00 (+2.43% weekly gain)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.135.70</div></div>\n <div class..." }, { "title": "Bafna Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Challenges", "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-valuation-shifts-signal-price-attractiveness-challenges-3960027", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_valuationdot_3960027.png", "date": "2026-04-24 08:00:33", "description": "Bafna Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, prompting a reassessment of its price attractiveness amid evolving market dynamics and peer comparisons within the Pharmaceuticals & Biotechnology sector." }, { "title": "Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5.87% Gain — Buyers Queue, Sellers Absent", "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-surges-to-upper-circuit-amid-strong-buying-pressure-3959504", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_stocks_hitting_upper_circuit_3959504.png", "date": "2026-04-23 15:00:08", "description": "At Rs 138.73, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5.87% on 23 Apr 2026, with buyers queuing and no sellers willing to part with shares." }, { "title": "Bafna Pharmaceuticals Declines 6.41% Amid Mixed Signals and Valuation Shift", "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-declines-641-amid-mixed-signals-and-valuation-shift-3952408", "imagepath": "", "date": "2026-04-18 15:00:05", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>13 Apr:</strong> Stock hits lower circuit amid heavy selling pressure</p>\n <p><strong>16 Apr:</strong> Technical and valuation improvements prompt rating upgrade</p>\n <p><strong>17 Apr:</strong> Stock surges to upper circuit on strong buying interest</p>\n <p><strong>17 Apr:</strong> Valuation shifts signal improved price attractiveness</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.145.00</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"sta..." }, { "title": "Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent", "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-pressure-3950959", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_stocks_hitting_upper_circuit_3950959.png", "date": "2026-04-17 12:00:09", "description": "At Rs 139.45, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5.0% on 16 Apr 2026, with buyers queuing and no sellers willing to part with shares." }, { "title": "Bafna Pharmaceuticals Ltd Upgraded to Sell on Technical and Valuation Improvements", "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-ltd-upgraded-to-sell-on-technical-and-valuation-improvements-3950258", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_mojoScore_3950258.png", "date": "2026-04-17 08:19:02", "description": "Bafna Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 Apr 2026, reflecting a nuanced improvement across technical indicators and valuation metrics despite ongoing challenges in financial performance. The micro-cap pharmaceutical company’s Mojo Score rose to 31.0, signalling a cautious but more favourable outlook amid mixed signals from quality and financial trends." } ], "total": 309, "sid": "852453", "stock_news_url": "https://www.marketsmojo.com/news/bafna-pharmaceuticals-852453" }, "announcements": [ { "details": "Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on November 13, 2019.", "source": "NSE", "caption": "Bafna Pharmaceuticals Limited - Outcome of Board Meeting", "datetime": "14-Nov-2019" }, { "details": " <table><tr><td>The Exchange had sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed. </td></tr></table>", "source": "NSE", "caption": "Reply to Clarification- Financial results", "datetime": "27-Aug-2019" }, { "details": " <table><tr><td>BAFNAPHARM: Members of the Exchange are hereby informed that the trading in Equity Shares of Bafna Pharmaceuticals Limited shall be suspended w.e.f. August 26, 2019 (i.e. closing hours of trading on August 23, 2019) on account of Reduction of Share Capital. </td></tr></table>", "source": "NSE", "caption": "Suspension of trading in equity shares", "datetime": "21-Aug-2019" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Bafna Pharmaceuticals Ltd has declared <strong>6%</strong> dividend, ex-date: 19 Sep 13", "dt": "2013-09-19", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

13 Apr: Stock hits lower circuit amid heavy selling pressure

16 Apr: Technical and valuation improvements prompt rating upgrade

17 Apr: Stock surges to upper circuit on strong buying interest

17 Apr: Valuation shifts signal improved price attractiveness

Week Open

Rs.145.00

Week Close

Read full news article

Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent

2026-04-17 12:00:09

At Rs 139.45, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5.0% on 16 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

Bafna Pharmaceuticals Ltd Upgraded to Sell on Technical and Valuation Improvements

2026-04-17 08:19:02

Bafna Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 Apr 2026, reflecting a nuanced improvement across technical indicators and valuation metrics despite ongoing challenges in financial performance. The micro-cap pharmaceutical company’s Mojo Score rose to 31.0, signalling a cautious but more favourable outlook amid mixed signals from quality and financial trends.

Read full news article